http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Bo Hyun Kim ),( Joong Won Park ),( Yeon Su Lee ),( Byung Chul Kim ),( Sung Hoon Lee ),( Seung Hyun Hong ),( Jung Ah Hwang ),( Jin Sook Kim ),( Jung Ahn Lee ),( Jong Bhak ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.-
Background: Sorafenib is the first systemic agent to show a survival benefit in patients with advanced HCC. Because there is a substantial portion of poor-responders to sorafenib, reliable biomarkers to predict the treatment response before initiation are urgently needed. The aim of this study was to identify genome variations associated with responsiveness of sorafenib in unresectable HCC patients who were treated with concurrent TACE-sorafenib trial or sorafenib only by whole genome analysis using recently developed Next Generation Sequencing technology. Methods: We obtained normal genomic DNAs from four good responders (median TTP 10.8months) and three poor responders (median TTP 3.8months) and analyzed their genome by whole-genome sequencing using 90 bp paired-end reads. Identified variations were validated by Sanger sequencing and further functional analysis was performed. Results: On average, 90 gigabases per sample were produced at ∼34X sequencing depth, and they were mapped to the reference genome at an over 95% mapping rate. A total of 1813 variations were found and 138 are from sorafenib target- and drug ADME genes. Among them, 36 SNVs were found in the coding genes and 8 SNVs from 5 genes (ABCB1, ALDH3B1, FMO3, MUSK, SLC15A2) were non-synonymous SNVs which may cause a functional protein damage. Interestingly, pathway analysis of 1813 ns SNVs revealed that drug metabolism pathway components were highly affected (p <0.01), suggesting that the genetic differences in patients resulted in the different responses to sorafenib treatment. Conclusions: We present the results of whole genome sequencing approach to identify sorafenib response markers and related genes in unresectable HCC patients. We found genome variations in known sorafenib targets and ADME genes. These variations may offer a great resource to identify HCC patients whose genetic types are predicted as advantageous for sorafenib treatment.
Basic : Diagnostic value of simplified criteria in korean patients with autoimmune hepatitis (초)
( Bo Hyun Kim ),( Yoon Jun Kim ),( Sang Youn Hwang ),( Sook Hyang Jeong ),( Won Young Tak ),( Sang Hoon Ahn ),( Youn Jae Lee ),( Eun Uk Jung ),( Jung Il Lee ),( Jong Eun Yeon ),( Jae Seok Hwang ),( So 대한간학회 2011 Clinical and Molecular Hepatology(대한간학회지) Vol.17 No.3(S)
( Bo Hyun Kim ),( Joong Won Park ),( Yeon Su Lee ),( Byung Chul Kim ),( Sung Hoon Lee ),( Seung Hyun Hong ),( Jung Ah Hwang ),( Jin Sook Kim ),( Jung Ahn Lee ),( Jong Bhak ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.1
Background: Sorafenib is the first systemic agent to show a survival benefit in patients with advanced HCC. Because there is a substantial portion of poor-responders to sorafenib, reliable biomarkers to predict the treatment response before initiation are urgently needed. The aim of this study was to identify genome variations associated with responsiveness of sorafenib in unresectable HCC patients who were treated with concurrent TACE-sorafenib trial or sorafenib only by whole genome analysis using recently developed Next Generation Sequencing technology. Methods: We obtained normal genomic DNAs from four good responders (median TTP 10.8months) and three poor responders (median TTP 3.8months) and analyzed their genome by whole-genome sequencing using 90 bp paired-end reads. Identified variations were validated by Sanger sequencing and further functional analysis was performed. Results: On average, 90 gigabases per sample were produced at ~34X sequencing depth, and they were mapped to the reference genome at an over 95% mapping rate. A total of 1813 variations were found and 138 are from sorafenib target- and drug ADME genes. Among them, 36 SNVs were found in the coding genes and 8 SNVs from 5 genes (ABCB1, ALDH3B1, FMO3, MUSK, SLC15A2) were non-synonymous SNVs which may cause a functional protein damage. Interestingly, pathway analysis of 1813 ns SNVs revealed that drug metabolism pathway components were highly affected (p <0.01), suggesting that the genetic differences in patients resulted in the different responses to sorafenib treatment. Conclusions: We present the results of whole genome sequencing approach to identify sorafenib response markers and related genes in unresectable HCC patients. We found genome variations in known sorafenib targets and ADME genes. These variations may offer a great resource to identify HCC patients whose genetic types are predicted as advantageous for sorafenib treatment.
Isolation of 151 Mutants that Have Developmental Defects from T-DNA Tagging
Ahn, Ji Hoon,Kim, Joonki,Yoo, Seong Jeon,Yoo, So Yeon,Roh, Hyungmin,Choi, Jun-Hyuk,Choi, Mi Suk,Chung, Kyung Sook,Han, Eun Ju,Hong, Sung Myun,Jung, Sung Hye,Kang, Hyo Jin,Kim, Bo Kyung,Kim, Mi Duk,Kim Oxford University Press 2007 Plant & cell physiology Vol.48 No.1
<P>In order to understand the mechanisms underlying plant development, a necessary first step involves the elucidation of the functions of the genes, via the analysis of mutants that exhibit developmental defects. In this study, an activation tagging mutant library harboring 80,650 independent <I>Arabidopsis</I> transformants was generated in order to screen for developmental mutants. A total of 129 mutants manifesting dominant developmental abnormalities were isolated, and their T-DNA insertion loci were mapped. The activation of one or more genes adjacent to a T-DNA insertion locus was confirmed in eight dominant mutants. A gene adjacent to the right border was usually activated by the 35S enhancers. Interestingly, the transcriptional activation of multiple genes within a broad range was observed in one of the mutants, which raises the possibility that activation by the 35S enhancers was not limited strictly to a single gene. In order to gain a better understanding of sexual reproduction in higher plants, we isolated 22 mutants exhibiting defects in female gametophyte development, and determined their T-DNA insertion loci. We propose that this mutant population may prove useful in the further determination of the functions of genes that play important roles in plant development.</P>